ASAnshul Shakya

Anshul Shakya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anshul Shakya has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Microwave‐Assisted Synthesis and In Vitro Anti‐Alzheimer Evaluation of Novel 1,3,5‐Triazine‐Nicotinic Hydrazide Derivatives as Acetylcholinesterase and Butyrylcholinesterase Inhibitors

    by Tutumoni Kalita, Anshul Shakya, Surajit Kumar Ghosh, Udaya Pratap Singh, Hans Raj Bhat

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder posing major global health challenges due to its complex pathophysiology and increasing prevalence among the elderly. In the present work, the molecular hybridization technique was utilized to design and synthesize nicotinic hydrazide‐1,3,5‐triazine hybrids. Accordingly, this study aimed to design, perform in silico screening, synthesize, and evaluate the in vitro and in vivo anti‐AD potential of the proposed compounds. Docking studies revealed that the compounds displayed key interactions with catalytic site and peripheral anionic site residues. Based on binding affinity, ten compounds were synthesized and characterized using different spectroscopic techniques. In vitro AChE and BChE inhibitory assays revealed that the compound 4A36 showed the highest inhibitory ability with log IC 50 values of 5.97 μM against AChE and 4.57 μM against BChE. In addition, cytotoxicity screening revealed that 4A36 was non‐toxic in SH‐SY5Y neuroblastoma cells in the concentration range of 15.625−250 µg/mL. Acute oral toxicity evaluation of the compound revealed no adverse effects up to 175 mg/kg b.w. Further, in vivo studies using the scopolamine‐induced model further validated the therapeutic promise of the compound. At a dose of 30 mg/kg b.w., the compound demonstrated significant improvements in learning and memory, reduced MDA levels with concurrent elevation of antioxidant enzymes SOD and Catalase, and reduced AChE activity in hippocampal tissue. Histopathological observations revealed that treatment groups, especially at higher dose (30 mg/kg b.w.), preserved the granular layer of the dentate gyrus and improved neuronal integrity compared to the disease control. These findings indicate that 4A36 at a dose of 30 mg/kg b.w. may be considered as a promising lead compound in AD.


  • Monoclonal Antibodies and Cancer

    by Sheikh Rezzak Ali, Gautam Saxena, Lipoksangla Jamir, Nasima Ahmed, Gireesh Kumar Singh, Hans Raj Bhat, Surajit Kumar Ghosh, Anshul Shakya


  • An in‐depth analysis of COVID‐19 treatment: Present situation and prospects

    by Ariful Islam, Kalyani Pathak, Riya Saikia, Pallab Pramanik, Aparoop Das, Prasenjit Talukdar, Anshul Shakya, Surajit Kumar Ghosh, Udaya Pratap Singh, Hans Raj Bhat

    Coronavirus disease 2019 (COVID‐19) the most contagious infection caused by the unique type of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), produced a global pandemic that wreaked havoc on the health‐care system, resulting in high morbidity and mortality. Several methods were implemented to tackle the virus, including the repurposing of existing medications and the development of vaccinations. The purpose of this article is to provide a complete summary of the current state and future possibilities for COVID‐19 therapies. We describe the many treatment classes, such as antivirals, immunomodulators, and monoclonal antibodies, that have been repurposed or developed to treat COVID‐19. We also looked at the clinical evidence for these treatments, including findings from observational studies and randomized‐controlled clinical trials, and highlighted the problems and limitations of the available evidence. Furthermore, we reviewed existing clinical trials and prospective COVID‐19 therapeutic options, such as novel medication candidates and combination therapies. Finally, we discussed the long‐term consequences of COVID‐19 and the importance of ongoing research into the development of viable treatments. This review will help physicians, researchers, and policymakers to understand the prevention and mitigation of COVID‐19.


  • A Review of Preclinical Tools to Validate Anti-Diarrheal Agents

    by Rajdeep Sarma, Anshul Shakya, Arka Karmakar, Surajit Kumar Ghosh, Hans Raj Bhat, Neha Ghimire, Obaidur Rahman

    Background: Since their inception, preclinical experimental models have played an important role in investigating and characterizing disease pathogenesis. These in vivo, ex vivo, and in vitro preclinical tests also aid in identifying targets, evaluating potential therapeutic drugs, and validating treatment protocols.Introduction: Diarrhea is a leading cause of mortality and morbidity, particularly among children in developing countries, and it represents a huge health-care challenge on a global scale. Due to its chronic manifestations, alternative anti-diarrheal medications must be tested and developed because of the undesirable side effects of currently existing anti-diarrheal drugs.Methods: Several online databases, including Science Direct, PubMed, Web of Science, Google Scholar and Scopus, were used in the literature search. The datasets were searched for entries of studies up to May, 2022.Results: The exhaustive literature study provides a large number of in vivo, in vitro and ex vivo models, which have been used for evaluating the mechanism of the anti-diarrheal effect of drugs in chemically-, pathogen-, disease-induced animal models of diarrhea. The advances and challenges of each model were also addressed in this review.Conclusion: This review encompasses diverse strategies for screening drugs with anti-diarrheal effects and covers a wide range of pathophysiological and molecular mechanisms linked to diarrhea, with a particular emphasis on the challenges of evaluating and predictively validating these experimental models in preclinical studies. This could also help researchers find a new medicine to treat diabetes more effectively and with fewer adverse effects.


  • Drug Development Projects Guided by Ethnobotany and Ethnopharmacology Studies

    by Sheikh Rezzak Ali, Shuby Kumari, Satyendra K. Prasad, Rupali S. Prasad, Saurabh K. Sinha, Anshul Shakya

  • Open Access

    A Systematic Overview of Monkeypox: from Origin to Treatment

    by Sheikh Rezzak Ali, Shahnaz Alom, Shuby Kumari, Farak Ali, Jakia Afruja, Gireesh Kumar Singh, Hans Raj Bhat, Surajit Kumar Ghosh, Anshul Shakya

    The objective of this paper is to analyze existing data related to the monkeypox virus, its genomic characterization, transmission, prevention, and treatment available considering the current scenario of the monkeypox outbreak globally and posing a threat to public health. The literature search was performed in databases including PubMed, Science Direct, and Google Scholar up to September 2022. The monkeypox virus is a re-emerging threat to international travel and public health that poses fresh difficulties. Due to these effects, the World Health Organization (WHO) declared a human monkeypox public health emergency of international concern on July 23, 2022. The illness can spread from animals to humans, from humans to animals, and possibly from humans to humans. However, humanto-human transmission of the monkeypox virus is much more uncommon than animal-to-human transmission. During the outbreak of monkeypox in 2022, 5 continents have shown test positive in less than three months. Most of the cases were in men who have sex with men. There are several methods for diagnosis like genetic method, phenotypic method, immunological method, and electron microscopy. To prevent the spreading of the monkeypox virus, numerous precautions can be taken such as avoiding direct or indirect contact with an infected person, vaccination, or specific medication.


  • Open Access

    Preclinical assessment of safety profile of hydro-alcoholic extract of Entada phaseoloides (L.) Merr. seed kernels

    by Lipoksangla Jamir, Surajit Kumar Ghosh, Hans Raj Bhat, Sushil Kumar Chaudhary, Anshul Shakya


  • Open Access

    Ethnobotany and Phytopharmacology of Avena sativa: A Qualitative Review

    by Shuby Kumari, Sheikh Rezzak Ali, Obaidur Rahman, Amit Kumar, Hans Raj Bhat, Surajit Kumar Ghosh, Anshul Shakya

    Among all cereals, oat is considered to be one of the goods consumed in functional grain, nutraceutical, and pharmaceutical components. The review article aims to explore plant profile, phytochemical constituents present in different parts, and potential therapeutic agent which prevents people from different diseases with their respective mechanism of action it also includes toxicity studies, dosage form, marketed formulation, and industrial application. The information on Avena sativa is collected from the different databases available in Science Direct, PubMed, Scopus, and Google Scholar to search for research papers for literature and data. Reviewed information suggests that the A. Sativa is a good source of a range of phytochemicals including lignans, saponin, anthocyanidins, and avenanthramides, which might be directly and/or indirectly linked with beneficial nutraceutical and/or pharmacological effect(s). The review states, that A. sativa is a promising candidate as a functional and/or non-functional food because of various phytoconstituents. The clinical report has described that the utilization of oats can provide several health benefits. However, systematic rational investigations for such indications and safety profiles are yet to be explored.


  • Open Access

    Subchronic toxicity study of the characterized hydroalcoholic extract of Paederia foetida (L.) leaves in swiss albino mice

    by Rajdeep Sarma, Neha Ghimire, Obaidur Rahman, Lipoksangla Jamir, Sushil Kumar Chaudhary, Siddharth Singh, Hans Raj Bhat, Surajit Kumar Ghosh, Anshul Shakya